Skip to main content

Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report



Maffucci syndrome (MS) is a rare, nonhereditary congenital mesodermal dysplasia characterized by multiple enchondromas and hemangiomas, associated with an increased risk of developing malignant tumors. Given their rarity, the pathogenesis of these tumors has not been clarified, and there is no standard treatment.

Case presentation

We present a case of a 45-year-old man with MS to supplement the clinical manifestations and explore the molecular mechanism of MS. The patient underwent amputation surgery to inhibit tumor development and was diagnosed with MS with 1–2 grade giant chondrosarcoma in the left ankle. In addition, the whole exon analysis results revealed isocitrate dehydrogenase 1 (IDH1) R132C mutation in chondrosarcoma lesions but not in blood DNA.


This case report showed MS complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation, which is appropriate to monitor the development of MS pathology and other concomitant lesions.


Maffucci syndrome (MS) is a rare cartilage dysplasia syndrome. In 1881, Angelo Maffucci first described a non-genetic disease characterized by multiple hemangiomas and endogenous chondroma during adolescence [1]. Clinically, MS is distinguished from Ollier disease (OD) by identifying soft-tissue vascular lesions accompanying MS but not OD. MS patients usually have asymmetric skeletal deformities and limb length differences in the first decade of life and may need surgery.

MS could occur in multiple races without gender differences or genetic predisposition. MS usually appears before the onset of puberty. However, 25% of the patients occurred at birth or within 1 year old, presenting with asymmetric leg contracture, swelling of the hands and feet, and occasionally fracture of the affected part. Endochondroma of MS grows slowly, with mild symptoms, local swelling, slight pain and tenderness, and pathological fractures. Often involving the iliac bone, metastasis is common in the lung [2].

Furthermore, additional tumors have been reported in MS patients with the disease progression, including lymphangiomas, glioma, acute myeloid leukemia, and ovarian fibrosarcoma [3, 4]. Recently, it has been revealed that individuals with MS and OD harbor somatic mosaicism of mutations in isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2), as the crucial factors in the pathogenesis of these diseases [5]. At present, there are few studies on MS with chondrosarcoma and detailed gene analysis.

Therefore, this article reports a case of giant chondrosarcoma secondary to MS with a long medical history. Moreover, we conducted whole-exome sequencing of germline DNA and chondrosarcoma tissue to further explore the pathogenesis of MS.

Case presentation

History of present illness

A 45-year-old male patient was admitted to our hospital in October 2020 because of a lump in the left ankle for 20 years and enlarging over the last 2 years. From the appearance of the lump to the subsequent 18 years, there were no significant changes. However, the left ankle lump enlarged rapidly about 40 cm in diameter and then developed skin ulceration with apparent purulent discharge 2 years ago.

History of past illness

At the age of 7, the patient accidentally found several soybean-sized soft lumps in two feet without pain and dysfunction, which was not paid attention to at that time. The patient developed multiple lumps in his limbs in the next few years. When the patient was 19 years old, he was finally diagnosed with MS for the extremities with multiple angiomatosis and enchondromas and underwent resection surgery in our hospital. However, the symptoms reoccurred at the original resection site only 2 years later and resection surgery again. Confusingly, reoccurrence happened soon after the second resection surgery.

Physical and imaging examination

After the patient was admitted in 2020, the physical examination showed multiple angiomatoses and enchondromas in the extremities (Fig. 1A, B), and a giant lump of about 35 cm × 30 cm × 30 cm in the left ankle, with local skin ulceration and evident purulent secretion discharge (Fig. 1C, D). There was a big lump on the right scapula without tenderness or percussion pain (Fig. 1E).

Fig. 1
figure 1

Physical examination. A, B Multiple angiomatoses and enchondromas in the extremities. C, D A giant lump in the left ankle. E A giant lump on the right scapula

X-ray examination of both hands revealed changes in bone morphology and density of both hands, including spherical expansive bone destruction in the right thumb and multiple phleboliths in the hands and wrists (Fig. 2A, B). In addition, we found bone density and morphological changes in the left ilium and left femur (Fig. 2C), the flexion deformity of the left knee joint, and multiple venous stones around the left knee joint (Fig. 2D). Moreover, X-ray examination showed local spherical expansive bone destruction with multiple calcifications at the left tarsal, multiple chondromatosis with bone deformity, and multiple hemangiomas (Fig. 2E, F). In addition, magnetic resonance imaging (MRI) was performed on the patient’s left femur to determine the amputation plane (Fig. 3). We found that the endogenous chondroma has involved the whole length of the left femur without chondrosarcoma; multiple patchy and nodular abnormal signals were observed in the left femur bone marrow cavity with low T1WI and high STIR signals. MRI examination also showed the swelling and exudation of the soft tissue around the femur surrounding soft tissue.

Fig. 2
figure 2

CT examination. A, B Spherical expansive bone destruction in the right thumb and multiple phleboliths in the hands and wrists. C Bone density and morphological changes of the left ilium and left femur. D Multiple venous stones around the left knee joint. E, F Spherical expansive bone destruction with multiple calcifications at the left tarsal

Fig. 3
figure 3

Preoperative imaging studies. A T1WI, the bone marrow cavity of the left femoris was dilated and irregular in shape, with multiple irregular patchy and nodular hyposignal foci (straight arrow). B, D The coronal, sagittal, and cross-sectional views of the STIR show the appearance of the lesion. T1WI shows the lesion with low-signal intensity. Inhomogeneous high signal, unclear boundary and adjacent cortical destruction in STIR ( straight arrow), surrounding soft tissue swelling, and exudation (curved arrow)

Oncological management

The patient was confirmed as having chondrosarcoma by biopsy prior to surgery. Although there were no typical appearances of MRI that demonstrated sarcoma metastasis, the patient’s knee has become stiff and nonfunctional. Therefore, the patient eventually underwent above-the-knee amputation. The tumor edge was saved 23 cm from the tibial tubercle. Therefore, surgical margins greater than 23 cm from the tumor meet the treatment criteria for wide excision. During the operation, clear fluid flowed out of the marrow cavity of the femur, and muscle edema was observed. Regrettably, the aspirator accidentally removed the liquid, leaving no specimen left. The surgical incision was sutured after intraoperative pathology confirmed the negative surgical margins. Most conventional chondrosarcomas have low metastatic potential and are both radiation and chemotherapy resistant, so the patient did not receive radiotherapy and chemotherapy after surgery.

Pathological examination

The resected specimen is shown in the supplementary material (Fig. S1A), and the tumors were apparent in Fig. S1B. The chondrosarcoma of the left ankle was assessed as grades 1–2 by pathological diagnosis. Multiple cavernous hemangiomas with thrombosis were in the left lower limb (Fig. 4A). Enchondroma was observed in the tibia. The cells were loose, with less atypia (Fig. 4B). Besides, chondrosarcoma invades surrounding soft tissues, and necrosis was seen in some areas (Fig. 4C). Chondrosarcoma cells with prominent atypia and visible nuclear fission (Fig. 4D).

Fig. 4
figure 4

Microscopical features of the pathological sections with hematoxylin–eosin staining. A Hemangioma, × 5. B Endochondroma, × 10. C, D Chondrosarcoma, × 10 and × 40, respectively

Genetic testing

DNA was extracted from the peripheral blood and chondrosarcoma tissue and performed exome sequencing. Genomic DNA from FFPE tumor samples and paired blood samples were extracted by QIAamp DNA FFPE Tissue KIT and QIAamp DNA Blood Midi KIT (Qiagen, Dusseldorf, Germany) following the manufacturer’s instructions, respectively. The QIAseq FX DNA Library UDI Kit (Qiagen, Dusseldorf, Germany) was used to generate indexed whole genome libraries from 50-ng genomic DNA according to handbook protocols. Hybridization capture was performed using the IDT xGen Exome Research Panel v1.0 (Integrated DNA Technologies, Coralville, IA, USA) according to the manufacturer’s protocol. Finally, whole exome libraries were quantified by qPCR using the QIAseq Library Quant Assay Kit on a QIAquant 384 instrument (Qiagen, Dusseldorf, Germany). Paired-end sequencing (2 × 150 bp) was performed on an Illumina NovaSeq 6000 sequencing instrument (Illumina, San Diego, CA, USA). Then, the data were mapped to the human reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA) [6]. Picard was used to removing duplicated sequence reads. The Genome Analysis Toolkit (GATK) [7] HaplotypeCaller and MuTect [8] were applied to identify candidate germline and somatic single-nucleotide variants (SNVs), respectively. SNV annotation was performed using ANNOVAR [9], and somatic copy number alterations were identified using CNVkit [10]. Somatic structural variations were detected using DELLY [11].

Finally, germline mutations of the tumor susceptibility gene were not discovered. However, a somatic missense mutation was identified in IDH1 gene compared with germline DNA variants (nucleotide variant: NM_005896.4: c.394 C > T, amino acid variant: NP_005887.2: p.Arg132Cys, rsID:rs121913499), which the mutation ratio was 14.71%. It has been recorded as pathogenic and likely pathogenic in ClinVar (Variation ID: 375,891). The frequency of this locus in normal East Asian populations has not been reported. Thus, IDH1 R132C, in our case classified as pathogenic.


We have followed up with the patient for 15 months, the wound is healing as well, and no obvious recurrence was observed at present (Fig. S1C). Hemangiomas and chondroma in other sites had no progress. In addition, the patient has been fitted with a prosthesis and can walk on the ground.


This article reports a case of giant chondrosarcoma secondary to MS. The patient had a 39-year history of MS and a 2-year history of chondrosarcoma in the left ankle. Due to the large size (40 cm in diameter) and the malignant of the left ankle chondrosarcoma, we performed an amputation surgery to inhibit the tumor development. For the first time, we conducted whole-exome sequencing of germline DNA and chondrosarcoma tissue in MS patient, revealing IDH1 R132C somatic mutation in chondrosarcoma lesions but not in blood DNA.

Enchondroma is a benign intramedullary chondroma that could occur at any position in MS patients. In our study, it develops on the bilateral scapula, the right fifth rib, both ilia, the left pubic branch, the left femur, the upper and lower ends of the tibia and fibula, and the metacarpal and phalanx. The risk of enchondroma developing into chondrosarcoma is approximately 25 to 30% in patients with MS, usually younger than primary chondrosarcoma patients [12]. Malignant changes frequently occur after 40 years old and could occur in any part of the affected bone. The pelvic and upper limb bones are more prone to malignant changes. Skull base chondrosarcoma accounted for 5 to 10% of all MS reports [13]. To the best of our knowledge, the female patient with MS developed chondrosarcoma of the femur at the age of 32 and a biliary adenocarcinoma at the age of 44 was described as early as 1987 [14]. Rarely it has been reported a 34-year-old man with tracheal chondrosarcoma and a 39-year-old woman with nasal cavity chondrosarcoma in MS patients [15, 16]. The patient in our study deteriorated to chondrosarcoma in the left ankle around 43 years old. It is remarkable that our MS patient complicated with chondrosarcoma in the ankle is very large and fast-growing, which is extremely rare among the MS reports.

A hemangioma can be seen in many parts, and 8.5% of individuals with MS will develop a vascular malignancy [17]. According to the National Organization for Rare Diseases, vascular abnormalities in MS patients generally occur in children ages 4–5 years, most commonly in the hands. Among individuals with MS, about half had unilateral vascular anomalies (47.2%), and 63% (63.8%) had vascular anomalies in the upper extremity, while 52.7% had them in the lower extremity, and only two individuals (5.5%) had visceral involvement [17]. In this case, multiple hemangiomas in both hands were observed.

We found IDH1 R132C somatic mutation in chondrosarcoma lesions in the present case. The IDH1 R132C has been detected previously in multiple tumor tissues. The most common missense mutation for the IDH1 Arg132 codon is histidine (IDH1 R132H). Others are also reported, such as cysteine, serine, glycine, leucine, or isoleucine [18, 19]. All these variants (IDH1(NM_005896.4)_ex4 c.395G > C (p.Arg132Pro), c.395G > T (p.Arg132Leu), c.395G > A (p.Arg132His), c.394C > A (p.Arg132Ser), and c.394C > G (p.Arg132Gly)) were all annotated as pathogenic or likely pathogenic in the ClinVar database (Variation ID: 375,890, 375,889, 156,444, 375,893, 375,892). The IDH1 R132C variant has been recorded in a COSMIC database for the blood and lymphatic system tumors, bone tumors, central nervous system tumors, biliary tumors, and other tumors (Genomic Mutation ID: COSV61615256). Variant R132C is also recorded in the CIViC database (Allele Registry ID: CA16602374).

IDH1 Arg132 residue locates at the enzyme affinity site for the substrate, which can catalyze isocitrate to produce α-ketoglutarate (α-KG). It is highly conserved during evolution and functionally important. Variant R132C is a gain-of-function mutation, changing the catalytic activity of the enzyme and resulting in the conversion of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG) [20, 21]. In normal cells, 2-HG is usually present at a very low level. However, excessive 2-HG may promote cell transformation by changing the redox state of cells or leading to metabolic and epigenetic changes [21, 22].

Literature showed that 77% of MS patients carry IDH1 or IDH2 mutations, which are often present in malignant tissues [23]. Recently, somatic mosaic IDH1 R132C variant in DNA derived from hemangioma tissue but absent in DNA derived from the blood was identified in an adult male with MS [24]. A 39-year-old MS woman together with intrahepatic cholangiocarcinoma (IHCC) showed IDH1 R132C mutation in the tumor tissue but not in the normal liver tissue and peripheral blood [4]. Furthermore, a MS patient with jugular foramen chondrosarcoma and pituitary adenoma revealed the same IDH1 R132C mutation in both tumors by Sanger sequencing [25]. Similarly, another report had shown common IDH1 R132C mutations in sellar, brainstem, and skull base tumors in MS patients; no IDH2 mutations were detected; and both IDH1 and IDH2 were wild types in blood DNA by Sanger sequencing [26]. However, no studies have shown that the same mutations are present in non-lesioned tissue or blood system. Our case revealed that the IDH1 R132C mutation was only present in the ankle chondrosarcoma tissue but not in the blood of this patient, and the presence of the mutation in the enchondroma/hemangioma tissue of the patient remains to be confirmed.

Consistently, the multiple enchondromas in OD and MS are the consequence of a post-zygotic germline mutation resulting in a mosaic distribution of mutant cells [27]. However, the culprit gene (S) is still elusive. Since IDH1/IDH2 mutations were detected in both isolated chondromas and tumors removed from patients with multiple lesions (OD/MS). Interestingly, some speculate that these mutations represent the early most synonymous genetic events and explain the onset of the disease. The detection of the same IDH1/IDH2 mutation in somatic tissues of the same patient but with low frequency will provide clear evidence for this. However, we demonstrated no mutation in the blood and could not prove mutations in non-invasive tissues in our case, which is difficult for patients with the mosaic disease.

Additionally, the same spectrum of mutations in IDH1 and IDH2 also leads to other malignancies. IDH1 and IDH2 mutations were first found in adult glioblastoma multiforme (GBM) patients [28]. Recurrent somatic mutations in IDH1 and IDH2 occurred in about 80% of patients with grade II–III GBM and secondary GBM, and it is an early event of GBM progression [29, 30]. IDH mutations were also found in 10–20% of patients with acute myeloid leukemia (AML), with a low incidence in other cancers; the majority of these lesions involve arginine (R) residue mutations in IDH1 codon 132 (IDH1 R132) and residues 140 and 172 of IDH2 (IDH2 R140 and IDH2 R172) [31, 32]. These findings suggested that somatic heterozygous mutations in IDH1 or IDH2 are also crucial in developing some malignant tumors. However, exactly how these variants contribute to this broad spectrum of diseases remains unclear.

The treatment of MS aims to alleviate the clinical symptoms of patients and detect malignant lesions early. Surgery is the primary treatment for bone and vascular diseases, and amputation should be considered for patients with severely affected functions or malignant changes. The essential biochemical indicator of IDH1 and IDH2 mutations in the peripheral blood is the abnormal increase of the 2-HG level [33], which may be a sensitive and specific predictor. The first oral IDH1 inhibitor Ivosidenib (AG-120) has been shown to reduce 2-HG levels and induce cell differentiation in vitro and in vivo [34]. More recently, sirolimus has been reported in two studies on the treatment of vascular lesions–one was unsuccessful; however, the other was successful when combined with surgical treatment [35, 36]. Nevertheless, no studies have shown that molecular therapy has successfully applied to MS patients, and we did not attempt adjuvant therapy.

The prognostic challenge of MS not only comes from the skeletal deformities and secondary limb length differences caused by itself but as well as the potential risk of malignant transformation into chondrosarcoma. Researchers conducted on 7 MS patients and showed that no patient died of skeletal sarcoma, but with non-skeletal malignancies in the study [14]. Therefore, in addition to routine clinical care for MS patients, clinicians should actively detect the development of endogenous chondromas in various parts and do well in tumor detection outside the bone tissue, such as the brain and abdomen.


This is a case report of MS complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation. To reduce missed diagnosis or early detection of concomitant lesions, imaging examination and follow-up of other organs are essential. Considering that no subsequent shared genetic events were identified in the chondrosarcoma from our limited analyses, it is critical to conduct a further comprehensive investigation to discover IDH1-associated tumorigenesis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Maffucci syndrome


Ollier disease


Isocitrate dehydrogenase


Magnetic resonance imaging




2-Hydroxyglutaric acid


Nicotinamide adenine dinucleotide phosphate




Secondary glioblastoma


Acute myeloid leukemia




  1. Pansuriya TC, Kroon HM, Bovée J. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol. 2010;3:557–69.

    PubMed  PubMed Central  Google Scholar 

  2. Verdegaal S, Bovee J, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC, Julian MS, Biau DJ, Van D, Leithner A. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist. 2011;16:1771–9.

    Article  Google Scholar 

  3. Auyeung J, Mohanty K, Tayton K. Maffucci lymphangioma syndrome: an unusual variant of Ollier’s disease, a case report and a review of the literature. Journal of Pediatric Orthopaedics B. 2003;12:147–50.

    Google Scholar 

  4. Prokopchuk O, Andres S, Becker K, Holzapfel K, Hartmann D, Friess H. Maffucci syndrome and neoplasms: a case report and review of the literature. BMC Res Notes. 2016;9:126.

    Article  Google Scholar 

  5. Amary MF, Damato S, Halai D, Eskandarpour M. erisha FB, onar FB, Mccarthy S, Fantin VR, Straley KS, Lobo S: Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43:1262–5.

    CAS  Article  Google Scholar 

  6. Li H, Durbin, Richard. Fast and accurate long-read alignment with Bur rows–Wheeler transform. Bioinformatics. 2010;26:589–95.

  7. Mckenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.

    CAS  Article  Google Scholar 

  8. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

    CAS  Article  Google Scholar 

  9. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.

  10. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016;12:e1004873.

  11. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:i333.

    CAS  Article  Google Scholar 

  12. Mahajan AM, Ganvir S, Hazarey V, Mahajan MC. Chondrosarcoma of the maxilla: a case report and review of literature. J Oral Maxillofacial Pathol. 2013;17:269–73.

    Article  Google Scholar 

  13. Adrianna R, Artur S. Do intracranial neoplasms differ in Ollier disease and maffucci syndrome? An in-depth analysis of the literature. Neurosurgery. 2009;65:1106–13.

    Article  Google Scholar 

  14. Schwartz HS, Zimmerman NB, Simon MA, Wroble RR, Millar EA, Bonfiglio M. The malignant potential of enchondromatosis. Jbone Joint Surga. 1987;69:269.

    CAS  Article  Google Scholar 

  15. Steinbichler TB, Kral F, Reinold S, Riechelmann H. Chondrosarcoma of the nasal cavity in a patient with Maffucci syndrome: case report and review of the literature. World Journal of Surgical Oncology. 2014;12:1–4.

    Article  Google Scholar 

  16. Wagnetz U, Patsios D, Darling G, Heras FL, Hwang D. Tracheal chondrosarcoma–a rare complication in Maffucci syndrome. Br J Radiol. 2009;82:178–81.

    Article  Google Scholar 

  17. Abiad JME, Robbins SM, Cohen B, Levin AS, Valle DL, Morris CD, Sobreira NLDM. Natural history of Ollier disease and Maffucci syndrome: patient survey and review of clinical literature. Am J Med Genet Part A. 2020;182:1093–103.

    Article  Google Scholar 

  18. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.

  19. Kang MR, Kim MS, Oh JE, Kim YR, Lee SH. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353–5.

    CAS  Article  Google Scholar 

  20. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27:599–608.

  21. Schaefer IM, Hornick JL, Bovée J. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Lab Invest. 2018;98:414–26.

    CAS  Article  Google Scholar 

  22. Losman JA, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836–52.

    CAS  Article  Google Scholar 

  23. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43:1256–61.

  24. Brown NJ, Ye Z, Stutterd C, Jayasinghe SI, Schneider A, Mullen S, Mandelstam SA, Hildebrand MS. Somatic IDH1 variant (p.R132C) in an adult male with Maffucci syndrome. Cold Spring Harb Mol Case Stud. 2021;7(6):a006127

  25. Hao S, Hong CS, Jie F, Yang C, Zhuang Z. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome. J Neurosurg. 2015;124:1.

    Google Scholar 

  26. Nejo T, Tanaka S, Ikemura M, Nomura M, Takayanagi S, Shin M, et al. Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report. J Neurosurg. 2018;131:1829–34.

  27. Erickson RP. Somatic gene mutation and human disease other than cancer. Mutat Res. 2010;705:96–106.

    CAS  Article  Google Scholar 

  28. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12.

  29. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481–98.

  30. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–53.

    CAS  Article  Google Scholar 

  31. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

    CAS  Article  Google Scholar 

  32. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.

  33. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.

  34. Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett. 2018;9:300–5.

  35. Lekwuttikarn R, Chang J, Teng J. Successful treatment of spindle cell hemangiomas in a patient with Maffucci syndrome and review of literatures. Dermatol Ther. 2019;32:e12919.

    Article  Google Scholar 

  36. Gupta V, Mridha AR, Khaitan BK. Unsatisfactory response to sirolimus in Maffucci syndrome-associated spindle cell hemangiomas. Dermatol Ther. 2019;32:e12851.

Download references


We would like to extend our deep gratitude to Prof. Ming Qi of Zhejiang University for his guidance and revision of this paper. We also appreciate Dr. Youmao Zheng of Taizhou Hospital of Zhejiang Province for his treatments of the pictures in supplementary material.


This work was supported by the Taizhou Science and Technology Planning Project (21ywb23, 1802ky01).

Author information

Authors and Affiliations



JHT collected the data. LHY and JHT drafted the manuscript and contributed to all other quality aspects of the study. ZMG and YH provided imaging help. LHR and XWM aided in pathology. ZRT, HZH, SB and LHY performed critical revision of the manuscript. ZW and QH aided in IDH1 R132C analysis and interpretation. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Rangteng Zhu.

Ethics declarations

Ethics approval and consent to participate

Our study were performed in accordance with ethical regulation and approved by the Medical Ethics Review Board Taizhou Hospital of Zhejiang Province, K20210718.

Consent for publication

Written informed consent for publication of the patient clinical details and clinical images were obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

 Fig. S1. The resected specimen and surgical site of the patient. (A) The resected specimen. (B) Apparent tumors in the resected specimen. (C) The surgical site of the patient.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lv, H., Jiang, H., Zhang, M. et al. Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report. World J Surg Onc 20, 218 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Maffucci syndrome
  • Chondrosarcoma
  • Isocitrate dehydrogenase